cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cassava Sciences Inc
41 own
22 watching
Current Price
$30.92
$-0.6
(-1.9%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,238.64M
52-Week High
52-Week High
62.49
52-Week Low
52-Week Low
13.84
Average Volume
Average Volume
1.08M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,238.64M
icon52-Week High62.49
icon52-Week Low13.84
iconAverage Volume1.08M
iconDividend Yield--
iconP/E Ratio--
What does the Cassava Sciences Inc do?
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer s disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Read More
How much money does Cassava Sciences Inc make?
News & Events about Cassava Sciences Inc.
Globe Newswire
11days ago
Figure 1 Statistical model of historical 1-year declines on ADAS-Cog, placebo vs simufilam treatment, mild-to-moderate disease. Figure 2 Statistical model of historical 1-year declines on ADAS-Cog, placebo vs simufilam treatment, in early disease and mild disease. ADAS-Cog mean scores changed...
Globe Newswire
1month ago
AUSTIN, Texas, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) announced today that a valued and long-time member of the Company, Nadav Friedmann, PhD, MD, has died following a brief journey with cancer, only recently discovered. We mourn profoundly the passing of a cherished...
Globe Newswire
1month ago
PHILADELPHIA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Investor protection law firm Kaskela Law LLC announces that it is investigating Cassava Sciences, Inc. (Cassava or the Company) (NASDAQ: SAVA) on behalf of the Companys long-term investors. On November 17, 2021, The Wall Street Journal reported that ...
Globe Newswire
2 months ago
Outside Biostatisticians with Specific Expertise in Alzheimers Disease Will Conduct an Independent Statistical Analysis on The Clinical Dataset. Clinical Dataset May Be Announced Approximately Year-End 2022, Pending Completion of Study Report by Outside Biostatisticians. AUSTIN, Texas, Dec. 06, 2022...
Globe Newswire
2 months ago
AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the Company or Cassava Sciences), a clinical-stage biotechnology company focused on Alzheimers disease, today announced the closing of its previously announced registered direct offering of 1,666,667 shares of ...
Frequently Asked Questions
Frequently Asked Questions
What is Cassava Sciences Inc share price today?
plus_minus_icon
Can Indians buy Cassava Sciences Inc shares?
plus_minus_icon
How can I buy Cassava Sciences Inc shares from India?
plus_minus_icon
Can Fractional shares of Cassava Sciences Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Cassava Sciences Inc stocks?
plus_minus_icon
What is today’s traded volume of Cassava Sciences Inc?
plus_minus_icon
What is today’s market capitalisation of Cassava Sciences Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Cassava Sciences Inc?
plus_minus_icon
What percentage is Cassava Sciences Inc down from its 52-Week High?
plus_minus_icon
What percentage is Cassava Sciences Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$30.92
$-0.6
(-1.9%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00